Controversies in the Therapy of Low-Grade Gliomas

Ivan D. Carabenciov, Jan Craig Buckner

Research output: Contribution to journalReview article

Abstract

In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

Original languageEnglish (US)
Article number25
JournalCurrent treatment options in oncology
Volume20
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Glioma
Neoplasms
Alkylating Agents
Therapeutics
Radiotherapy
Recurrence
Mutation

Keywords

  • Controversy
  • IDH mutation
  • Low-grade glioma
  • PCV
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Controversies in the Therapy of Low-Grade Gliomas. / Carabenciov, Ivan D.; Buckner, Jan Craig.

In: Current treatment options in oncology, Vol. 20, No. 4, 25, 01.04.2019.

Research output: Contribution to journalReview article

@article{75e9a89e085e485c85176c3c85fdd154,
title = "Controversies in the Therapy of Low-Grade Gliomas",
abstract = "In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.",
keywords = "Controversy, IDH mutation, Low-grade glioma, PCV, Temozolomide",
author = "Carabenciov, {Ivan D.} and Buckner, {Jan Craig}",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s11864-019-0625-6",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Controversies in the Therapy of Low-Grade Gliomas

AU - Carabenciov, Ivan D.

AU - Buckner, Jan Craig

PY - 2019/4/1

Y1 - 2019/4/1

N2 - In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

AB - In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

KW - Controversy

KW - IDH mutation

KW - Low-grade glioma

KW - PCV

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85062975797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062975797&partnerID=8YFLogxK

U2 - 10.1007/s11864-019-0625-6

DO - 10.1007/s11864-019-0625-6

M3 - Review article

C2 - 30874903

AN - SCOPUS:85062975797

VL - 20

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

M1 - 25

ER -